A1 Refereed original research article in a scientific journal
The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective
Authors: Bousquet Jean, Jutel Marek, Pfaar Oliver, Fonseca Joao A., Agache Ioana, Czarlewski Wienczyslawa, Bachert Claus, Bergmann Karl Christian, Cruz Alvaro A., Klimek Ludger, Kvedariene Violeta, Larenas-Linnemann Désirée E., Papadopoulos Nikolaos G., Patella Vincenzo, Regateiro Frederico S., Scichilone Nicola, Shamji Mohamed H., Sheikh Aziz, Valovirta Erkka, Ventura Maria-Teresa, Zuberbier Torsten
Publisher: American Academy of Allergy, Asthma and Immunology
Publication year: 2021
Journal: Journal of Allergy and Clinical Immunology: In Practice
Journal name in source: Journal of Allergy and Clinical Immunology: In Practice
Volume: 9
Issue: 5
First page : 1805
Last page: 1812
ISSN: 2213-2198
eISSN: 2213-2201
DOI: https://doi.org/10.1016/j.jaip.2021.02.035
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology.
